Skip to main content

Featured

Diwali: The Festival of Lights and Togetherness

Diwali, also known as Deepavali, is one of the most celebrated festivals in India and across the world. Symbolizing the triumph of light over darkness and good over evil, it brings families, friends, and communities together in a spirit of joy and renewal. The celebrations usually begin with cleaning and decorating homes, often with colorful rangoli patterns and rows of glowing diyas (oil lamps). Fireworks light up the night sky, while the aroma of festive sweets and savory dishes fills the air. People exchange gifts and sweets as a gesture of love and goodwill, strengthening bonds within families and neighborhoods. Beyond its vibrant traditions, Diwali also carries deep cultural and spiritual meaning. For many, it marks the return of Lord Rama to Ayodhya after defeating Ravana, while others honor Goddess Lakshmi, the bringer of prosperity. Regardless of the story, the essence remains the same: spreading light, hope, and positivity. In today’s world, Diwali has also become a global...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment